{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:48:34Z","timestamp":1648727314546},"reference-count":29,"publisher":"AACN Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,15]]},"DOI":"10.4037\/aacnacc2020436","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T20:47:05Z","timestamp":1584132425000},"page":"86-91","source":"Crossref","is-referenced-by-count":0,"title":["Spinal Muscular Atrophy in the Age of Gene Therapy"],"prefix":"10.4037","volume":"31","author":[{"given":"Lori","family":"Williams","sequence":"first","affiliation":[{"name":"Lori Williams is Clinical Nurse Specialist, Pediatric Universal Care Unit and Float Team, American Family Children\u2019s Hospital, University of Wisconsin Hospitals and Clinics, 1675 Highland Avenue, Room 7404, Madison, WI 53792 ()."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"suppl 1","key":"2020031316491171500_b1-0310086","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S1525-0016(16)33289-0","article-title":"480. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes","volume":"24","author":"Mendell","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"2020031316491171500_b2-0310086","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Panethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"2020031316491171500_b3-0310086","unstructured":"Yeager\n              A\n            \n          . FDA approves gene therapy for spinal muscular atrophy. The Scientist. https:\/\/www.the-scientist.com\/news-opinion\/fda-approves-gene-therapy-for-spinal-muscular-atrophy-65935. Published May 27, 2019. Accessed October 26, 2019."},{"issue":"5","key":"2020031316491171500_b4-0310086","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"2","key":"2020031316491171500_b5-0310086","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"2020031316491171500_b6-0310086","unstructured":"Rosenfeld\n              J\n            , ArmonC. Spinal muscular atrophy clinical presentation. Medscape. https:\/\/emedicine.medscape.com\/article\/1181436-clinical. Updated May 29, 2019. Accessed October 26, 2019."},{"issue":"(12)(suppl)","key":"2020031316491171500_b7-0310086","first-page":"S3","article-title":"Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2020031316491171500_b8-0310086","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Ferner","year":"2017","journal-title":"Ann Neurol"},{"key":"2020031316491171500_b9-0310086","unstructured":"Farooq\n              FT\n            , HolcikM, MackenzieA. Spinal muscular atrophy: classification, diagnosis, background, molecular mechanism and development of therapies. In KishoreU, ed. Neurodegenerative Diseases. London: IntechOpen;2013. https:\/\/https:\/\/www.intechopen.com\/books\/neurodegenerative-diseases\/spinal-muscular-atrophy-classification-diagnosis-background-molecular-mechanism-and-development-of-t. Accessed October 26, 2019."},{"issue":"1","key":"2020031316491171500_b10-0310086","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"2020031316491171500_b11-0310086","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New Engl J Med"},{"issue":"9","key":"2020031316491171500_b12-0310086","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"2020031316491171500_b13-0310086","unstructured":"Kollo\n              SJ\n            \n          . Longitudinal results from the NeuroNeXT SMA Infant Biomarker study. Paper presented at: 2016 SMA Researcher Meeting, June 15-19, 2016, Anaheim, CA. https:\/\/www.curesma.org\/sma-researcher-meeting\/#. Accessed October 26, 2019."},{"issue":"20","key":"2020031316491171500_b14-0310086","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type I","volume":"69","author":"Oskowi","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"2020031316491171500_b15-0310086","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"2020031316491171500_b16-0310086","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New Engl J Med"},{"key":"2020031316491171500_b17-0310086","volume-title":"Spinraza [prescribing information]"},{"issue":"7","key":"2020031316491171500_b18-0310086","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinergen versus sham control in later onset spinal muscle atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"New England J Med"},{"issue":"10063","key":"2020031316491171500_b19-0310086","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinergen: a phase 2, open label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"2020031316491171500_b20-0310086","doi-asserted-by":"crossref","unstructured":"Medrano\n              K\n            \n          . Is health care a right? Spinal muscular atrophy drug with outrageous price tag cuts to heart of ethical dilemma. Newsweek. https:\/\/www.newsweek.com\/health-care-right-spinal-muscular-atrophy-drug-outrageous-price-tag-cuts-heart-743757. Published December 11, 2017. Accessed October 27, 2019.","DOI":"10.1097\/00152193-201711000-00025"},{"key":"2020031316491171500_b21-0310086","unstructured":"Jones\n              G\n            \n          . Biogen\u2019s Spinraza overpriced, says ICER. Clinical Supply Chain Europe. 2019. http:\/\/www.pmlive.com\/pharma_news\/biogens_spinraza_overpriced_says_icer_1283420. Published April 4, 2019. Accessed October 27, 2019."},{"key":"2020031316491171500_b22-0310086","unstructured":"Weisman\n              R\n            \n          . Hope for devastating child disease comes at a cost: $750,000 a year. Boston Globe. https:\/\/www.bostonglobe.com\/business\/2017\/03\/27\/spinraza\/QnBmQrcmLLfUwvJunn0P8K\/story.html. Published March 27, 2017. Accessed October 27, 2019."},{"key":"2020031316491171500_b23-0310086","unstructured":"HHS Secretary, Alex Azar, recommends nationwide newborn screening for SMA. CureSMA. https:\/\/www.curesma.org\/hhs-secretary-recommends-nationwide-newborn-screening-for-sma. July4, 2018. Accessed July 14, 2019."},{"key":"2020031316491171500_b24-0310086","unstructured":"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease. Released May 24, 2019. Accessed July 14, 2019."},{"key":"2020031316491171500_b25-0310086","unstructured":"AveXis receives FDA approval for Zolgensma, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA). Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy. May24, 2019. Accessed October 26, 2019."},{"key":"2020031316491171500_b26-0310086","volume-title":"Zolgensma [prescribing information]","year":"2019"},{"key":"2020031316491171500_b27-0310086","unstructured":"Novartis\n          . Zolgensma clinical data. Presented at: American Academy of Neurology Annual Meeting, May 8, 2019. https:\/\/www.novartis.com\/sites\/www.novartis.com\/files\/2019-05-novartis-avexis-aan-presentation.pdf."},{"key":"2020031316491171500_b28-0310086","unstructured":"CureSMA\n          . Therapeutic approaches. 2019. https:\/\/www.curesma.org\/therapeuticapproaches. Accessed 10\/27\/19."},{"key":"2020031316491171500_b29-0310086","unstructured":"Almeida\n              MJ\n            \n          . Olesoxime (TRO19622). SMA News Today. https:\/\/smanewstoday.com\/olesoxime-tro19622-roche. Published 2019. Accessed October 27, 2019."}],"container-title":["AACN Advanced Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/aacnacconline\/article-pdf\/31\/1\/86\/125929\/86.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/aacnacconline\/article-pdf\/31\/1\/86\/125929\/86.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T20:49:37Z","timestamp":1584132577000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/aacnacconline\/article\/31\/1\/86\/30871\/Spinal-Muscular-Atrophy-in-the-Age-of-Gene-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3,15]]}},"URL":"https:\/\/doi.org\/10.4037\/aacnacc2020436","relation":{},"ISSN":["1559-7768","1559-7776"],"issn-type":[{"value":"1559-7768","type":"print"},{"value":"1559-7776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]}}}